<DOC>
	<DOCNO>NCT00097019</DOCNO>
	<brief_summary>This open-label , single-arm , two-stage , multicenter Phase II study evaluate efficacy safety bevacizumab woman platinum resistant , advance ( Stage III IV ) EOC ( epithelial ovarian cancer ) PPC ( primary peritoneal cancer ) subsequently progress either treatment Doxil Hycamtin therapy within 3 month discontinue treatment Doxil Hycamtin therapy .</brief_summary>
	<brief_title>A Study Bevacizumab Ovarian Cancer Primary Peritoneal Cancer Where Doxil Topotecan Therapy Has Failed</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Signed informed consent Female , age &gt; =18 year Advanced ( Stage III IV ) , histologically document epithelial ovarian cancer primary peritoneal cancer Platinumresistant disease Platinumresistant disease subsequently progress either treatment Doxil ( R ) Hycamtin ( R ) therapy within 3 month discontinue treatment Doxil ( R ) Hycamtin ( R ) therapy Received three treatment regimens Measurable disease least one lesion accurately measure least one dimension ( long dimension record ) accord RECIST ( exception spiral CT scan 8mm slice thickness accept ) Recovered prior cancer therapy ( XRT , surgery , chemotherapy ) ECOG performance status 0 1 Life expectancy &gt; 12 week Use effective mean contraception ( woman childbearing potential ) Four treatment regimens Prior therapy bevacizumab VEGF pathwaytargeted therapy Current , recent ( within 4 week first infusion bevacizumab ) , plan treatment experimental drug Genentechsponsored bevacizumab cancer study Screening clinical laboratory value : Granulocyte count &lt; 1500/uL ; Platelet count &lt; 75,000/uL ; Hemoglobin &lt; 8.5 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbopoeitin [ Aranesp ( R ) ] permit ) ; Serum bilirubin &gt; 2.0 x upper limit normal ( ULN ) ; Alkaline phosphatase , AST , ALT &gt; 2.5 x ULN ( AST , ALT &gt; 5 x ULN subject liver metastasis ) ; Serum creatinine &gt; 2.0 ; International normalize ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; 1.5 x ULN ( except subject receive anticoagulation therapy ) ; Urine protein/creatinine ratio &gt; 1.0 screen Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix B ) . Women receive prior Doxil ( R ) therapy ejection fraction &lt; 50 % exclude study . History myocardial infarction within 6 month prior Day 0 ( day first bevacizumab infusion ) History stroke transient ischemic attack within 6 month prior Day 0 Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 ; anticipation need major elective surgical procedure course study Minor surgical procedure , fine needle aspiration , core biopsy within 7 day prior Day 0 History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Presence central nervous system brain metastasis History malignancy within 5 year Day 0 , except adequately treat carcinoma situ cervix , ductal carcinoma situ ( DCIS ) breast , basal squamous cell skin cancer Pregnant ( positive pregnancy test ) lactate Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Recurrent ovarian cancer</keyword>
	<keyword>Refractory ovarian cancer</keyword>
</DOC>